Merkel Cell Carcinoma: Clinical Challenges and New Developments
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2609
Special Issue Editor
Special Issue Information
Dear Colleagues,
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer and its incidence has quadrupled in the past 20 years. Despite the recent approval of immune checkpoint inhibitors (ICI), their effective clinical use is encumbered by a high rate of resistance; moreover, clinical trials targeting genetic mutations and ICI resistance have not been successful. Currently there is no effective therapy for about 50% of MCC patients who are not candidates for ICIs and who have primary and acquired resistance to them. Since its discovery in 2008, MCC tumor heterogeneity has been attributed to variant disease etiologies, mediated by UV exposure or Merkel cell polyomavirus (MCPyV). Compared to MCPyV-positive MCCs, tumors without detectable MCPyV harbor a high tumor mutation burden with ultraviolet signatures. However, over the years, it has become clear that these two groups are largely similar in their clinical presentation, prognosis, and treatment response to ICIs. Thus, there is an urgent need to better understand heterogeneous MCC biology and uncover novel approaches that complement and extend current therapy.
Dr. Ling Gao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Merkel cell carcinoma
- immuno-oncology
- resistance mechanisms
- novel therapies
- Merkel cell polyomavirus
- biomarkers
- vaccine